Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Saved in:
| Title: | Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. |
|---|---|
| Authors: | Galanis E; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Anderson SK; Department of Oncology, Mayo Clinic, Rochester, Minnesota.; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Miller CR; Pathobiology and Translational Science Graduate Program, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina., Sarkaria JN; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota., Jaeckle K; Department of Neurology, Mayo Clinic, Jacksonville, Minnesota., Buckner JC; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Ligon KL; Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts., Ballman KV; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Moore DF Jr; Department of Internal Medicine, Cancer Center of Kansas, Wichita, Kansas., Nebozhyn M; Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, Pennsylvania., Loboda A; Data Analysis, Informatics & Analysis Department, Merck Research Laboratories, Boston, Massachusetts., Schiff D; Neuro-Oncology Center, University of Virginia School of Medicine, Charlottesville, Virginia., Ahluwalia MS; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Lee EQ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gerstner ER; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts., Lesser GJ; Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina., Prados M; Department of Neurological Surgery, University of California San Francisco, San Francisco, California., Grossman SA; Department of Oncology, Medicine & Neurosurgery, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Cerhan J; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota., Giannini C; Department of Pathology, Mayo Clinic, Rochester, Minnesota., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
| Corporate Authors: | Alliance for Clinical Trials in Oncology and ABTC |
| Source: | Neuro-oncology [Neuro Oncol] 2018 Mar 27; Vol. 20 (4), pp. 546-556. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 29016887 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Galanis+E%22">Galanis E</searchLink>; Department of Oncology, Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Anderson+SK%22">Anderson SK</searchLink>; Department of Oncology, Mayo Clinic, Rochester, Minnesota.; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Miller+CR%22">Miller CR</searchLink>; Pathobiology and Translational Science Graduate Program, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Sarkaria+JN%22">Sarkaria JN</searchLink>; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Jaeckle+K%22">Jaeckle K</searchLink>; Department of Neurology, Mayo Clinic, Jacksonville, Minnesota.<br /><searchLink fieldCode="AU" term="%22Buckner+JC%22">Buckner JC</searchLink>; Department of Oncology, Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Ligon+KL%22">Ligon KL</searchLink>; Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Ballman+KV%22">Ballman KV</searchLink>; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Moore+DF+Jr%22">Moore DF Jr</searchLink>; Department of Internal Medicine, Cancer Center of Kansas, Wichita, Kansas.<br /><searchLink fieldCode="AU" term="%22Nebozhyn+M%22">Nebozhyn M</searchLink>; Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Loboda+A%22">Loboda A</searchLink>; Data Analysis, Informatics & Analysis Department, Merck Research Laboratories, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Schiff+D%22">Schiff D</searchLink>; Neuro-Oncology Center, University of Virginia School of Medicine, Charlottesville, Virginia.<br /><searchLink fieldCode="AU" term="%22Ahluwalia+MS%22">Ahluwalia MS</searchLink>; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.<br /><searchLink fieldCode="AU" term="%22Lee+EQ%22">Lee EQ</searchLink>; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Gerstner+ER%22">Gerstner ER</searchLink>; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Lesser+GJ%22">Lesser GJ</searchLink>; Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina.<br /><searchLink fieldCode="AU" term="%22Prados+M%22">Prados M</searchLink>; Department of Neurological Surgery, University of California San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Grossman+SA%22">Grossman SA</searchLink>; Department of Oncology, Medicine & Neurosurgery, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Cerhan+J%22">Cerhan J</searchLink>; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Giannini+C%22">Giannini C</searchLink>; Department of Pathology, Mayo Clinic, Rochester, Minnesota.<br /><searchLink fieldCode="AU" term="%22Wen+PY%22">Wen PY</searchLink>; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22Alliance+for+Clinical+Trials+in+Oncology+and+ABTC%22">Alliance for Clinical Trials in Oncology and ABTC</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100887420%22">Neuro-oncology</searchLink> [Neuro Oncol] 2018 Mar 27; Vol. 20 (4), pp. 546-556. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100887420 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1523-5866 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215228517%22">15228517 </searchLink><i>NLM ISO Abbreviation: </i>Neuro Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29016887 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/neuonc/nox161 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 546 Titles: – TitleFull: Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Galanis E – PersonEntity: Name: NameFull: Anderson SK – PersonEntity: Name: NameFull: Miller CR – PersonEntity: Name: NameFull: Sarkaria JN – PersonEntity: Name: NameFull: Jaeckle K – PersonEntity: Name: NameFull: Buckner JC – PersonEntity: Name: NameFull: Ligon KL – PersonEntity: Name: NameFull: Ballman KV – PersonEntity: Name: NameFull: Moore DF Jr – PersonEntity: Name: NameFull: Nebozhyn M – PersonEntity: Name: NameFull: Loboda A – PersonEntity: Name: NameFull: Schiff D – PersonEntity: Name: NameFull: Ahluwalia MS – PersonEntity: Name: NameFull: Lee EQ – PersonEntity: Name: NameFull: Gerstner ER – PersonEntity: Name: NameFull: Lesser GJ – PersonEntity: Name: NameFull: Prados M – PersonEntity: Name: NameFull: Grossman SA – PersonEntity: Name: NameFull: Cerhan J – PersonEntity: Name: NameFull: Giannini C – PersonEntity: Name: NameFull: Wen PY IsPartOfRelationships: – BibEntity: Dates: – D: 27 M: 03 Text: 2018 Mar 27 Type: published Y: 2018 Identifiers: – Type: issn-electronic Value: 1523-5866 Numbering: – Type: volume Value: 20 – Type: issue Value: 4 Titles: – TitleFull: Neuro-oncology Type: main |
| ResultId | 1 |